Regulation of lncRNA PVT1 on miR-125 in metastasis of gastric cancer cells

Niu,Jiatai; Song,Xiangxin; Zhang,Xiaomei

doi:10.3892/ol.2019.11195

Regulation of lncRNA PVT1 on miR-125 in metastasis of gastric cancer cells

Authors:
- Jiatai Niu
- Xiangxin Song
- Xiaomei Zhang
View Affiliations

Affiliations: Department of Gastroenterology, Jinan Zhangqiu District Hospital of TCM, Jinan, Shandong 250200, P.R. China, Department of Burn and Plastic Surgery, Jinan Zhangqiu District Hospital of TCM, Jinan, Shandong 250200, P.R. China, Department of Oncology, Jinan Zhangqiu District Hospital of TCM, Jinan, Shandong 250200, P.R. China
Published online on: December 10, 2019 https://doi.org/10.3892/ol.2019.11195
Pages: 1261-1266
Copyright: © Niu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Regulation of long non‑coding RNA (lncRNA) PVT1 on miR‑125 affecting the metastasis of gastric cancer cells and the mechanism were investigated. qPCR was used to detect the expression of PVT1 and miR‑125 in gastric cancer and paracancerous tissues, and the relationship between PVT1 and clinicopathological parameters of gastric cancer patients. Dual luciferase reporter gene was used to detect the mutual effect between PVT1 and miR‑125. The clone formation assay was used to detect changes of proliferation behavior of gastric cancer cells after inhibition of PVT1. Transwell invasion assay was used to detect the changes of invasion ability of gastric cancer cells after inhibition of PVT1. Subcutaneous tumor formation in nude mice inhibited the effect of PVT1 on the tumor size and volume of gastric cancer cells. Compared with paracancerous tissues, the expression of PVT1 and miR‑125 was significantly increased in gastric cancer tissues. There were no significant differences in the expression level of PVT1 between gastric cancer patients of different genders and ages. The higher the gastric cancer staging was, the more obvious the expression level of PVT1 in the tissues of patients with gastric cancer was, and the more obvious the expression of PVT1 in the tissues of patients with gastric lymph node metastasis was. PVT1 specifically bound to the 3'UTR of miR‑125, whereas the inhibition of PVT1 inhibited the ability of proliferation and invasion of gastric cancer cells. In vitro experiment of tumor formation in nude mice showed that the tumor volume and weight of the tumor‑bearing mice in the si‑PVT1 group were significantly reduced. PVT1 plays an important role in the occurrence and development of gastric cancer, it can regulate the proliferation and invasion of gastric cancer cells by targeting miR‑125 activity.

View Figures

View References

1	Plummer M, Franceschi S, Vignat J, Forman D and de Martel C: Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 136:487–490. 2015. View Article : Google Scholar : PubMed/NCBI
2	Anderson WF, Rabkin CS, Turner N, Fraumeni JF Jr, Rosenberg PS and Camargo MC: The changing face of noncardia gastric cancer incidence among US non-hispanic whites. J Natl Cancer Inst. 110:608–615. 2018. View Article : Google Scholar : PubMed/NCBI
3	Mocellin S, Verdi D, Pooley KA and Nitti D: Genetic variation and gastric cancer risk: A field synopsis and meta-analysis. Gut. 64:1209–1219. 2015. View Article : Google Scholar : PubMed/NCBI
4	Huang Z, Zhu D, Wu L, He M, Zhou X, Zhang L, Zhang H, Wang W, Zhu J, Cheng W, et al: Six serum-based miRNAs as potential diagnostic biomarkers for gastric cancer. Cancer Epidemiol Biomarkers Prev. 26:188–196. 2017. View Article : Google Scholar : PubMed/NCBI
5	Ma J, Shen H, Kapesa L and Zeng S: Lauren classification and individualized chemotherapy in gastric cancer. Oncol Lett. 11:2959–2964. 2016. View Article : Google Scholar : PubMed/NCBI
6	Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC and Yu J: LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 35:2746–2755. 2016. View Article : Google Scholar : PubMed/NCBI
7	Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, Xie M, Xu L, De W, Wang Z, et al: LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res. 76:6299–6310. 2016. View Article : Google Scholar : PubMed/NCBI
8	Huang C, Yu W, Wang Q, Cui H, Wang Y, Zhang L, Han F and Huang T: Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med. 106:143–149. 2015.PubMed/NCBI
9	Zhao L, Kong H, Sun H, Chen Z, Chen B and Zhou M: LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448. J Cell Physiol. 233:4044–4055. 2018. View Article : Google Scholar : PubMed/NCBI
10	Liu HT, Fang L, Cheng YX and Sun Q: LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a. Cancer Med. 5:3512–3519. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yu J, Han J, Zhang J, Li G, Liu H, Cui X, Xu Y, Li T, Liu J and Wang C: The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. Medicine (Baltimore). 95:e44362016. View Article : Google Scholar : PubMed/NCBI
12	Yoshida K, Toden S, Ravindranathan P, Han H and Goel A: Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. Carcinogenesis. 38:1036–1046. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J, Zhou Z, Zhang W, Qin L and Huang G: LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 37:4094–4109. 2018. View Article : Google Scholar : PubMed/NCBI
14	Liu Z, Chen Z, Fan R, Jiang B, Chen X, Chen Q, Nie F, Lu K and Sun M: Over-expressed long noncoding RNA HOXA11-AS promotes cell cycle progression and metastasis in gastric cancer. Mol Cancer. 16:822017. View Article : Google Scholar : PubMed/NCBI
15	Shi SJ, Wang LJ, Yu B, Li YH, Jin Y and Bai XZ: LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 6:11652–11663. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zhou M, Hou Y, Yang G, Zhang H, Tu G, Du YE, Wen S, Xu L, Tang X, Tang S, et al: LncRNA-Hh strengthen cancer stem cells generation in twist-positive breast cancer via activation of Hedgehog signaling pathway. Stem Cells. 34:55–66. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, Zhong Z and Sun J: Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget. 7:32433–32448. 2016.PubMed/NCBI
18	Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, et al: The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 7:127912016. View Article : Google Scholar : PubMed/NCBI
19	Huang T, Liu HW, Chen JQ, Wang SH, Hao LQ, Liu M and Wang B: The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. Biomed Pharmacother. 88:302–308. 2017. View Article : Google Scholar : PubMed/NCBI
20	Shen CJ, Cheng YM and Wang CL: LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target. 25:637–644. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD and Wang ZX: Long noncoding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol Cancer Ther. 15:1082–1094. 2016. View Article : Google Scholar : PubMed/NCBI
22	Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, et al: Racial and ethnic differences in breast cancer survival: Mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 33:2254–2261. 2015. View Article : Google Scholar : PubMed/NCBI
23	Krammer J, Pinker-Domenig K, Robson ME, Gönen M, Bernard-Davila B, Morris EA, Mangino DA and Jochelson MS: Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 163:565–571. 2017. View Article : Google Scholar : PubMed/NCBI
24	Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DS, Henderson LM and Smith RA; Breast Cancer Surveillance Consortium, : Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. JAMA Oncol. 1:1069–1077. 2015. View Article : Google Scholar : PubMed/NCBI
25	Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY, Gong W and Quan ZW: Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 6:e15832015. View Article : Google Scholar : PubMed/NCBI
26	Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW, et al: Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 136:2616–2627. 2015. View Article : Google Scholar : PubMed/NCBI